Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Partners with BioMarin on PARP Inhibitor

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Myriad Genetics has signed an agreement with BioMarin Pharmaceutical to perform BRCA1 and BRCA 2 mutation testing for the drug firm's PARP inhibitor drug candidate, Myriad said after the close of the market on Wednesday.

The testing will be done on patients enrolled in BioMarin's Phase I and Phase II clinical study of its PARP inhibitor called BMN 673 for patients with advanced or recurrent tumors.

Financial and other terms of the deal were not disclosed.

Myriad will conduct Comprehensive BRACAnalysis with large rearrangement testing to identify the presence of germline mutations in the patients prior to enrolling in BioMarin's study. Myriad will also provide standard test reports to the clinicians.

The deal is the third between Myriad and pharmaceutical firms to use BRACAnalysis to determine the effectiveness of PARP inhibitors. Myriad has similar deals with Abbott and AstraZeneca for their candidate drugs.

Dane Leone, an analyst with Macquarie Capital, wrote in a research note on Wednesday — when his firm initiated coverage of Myriad — that Abbott is currently in Phase II clinical trials for its drug called ABT-888 for breast cancer. Patients in the study were stratified by BRCA 1 and BRCA 2 mutation. A Phase IIb study is expected to start later this year, and Leone said results from that trial will not be disclosed until late 2012 or 2013.

AstraZeneca expects a Phase III clinical trial for its olaparib PARP inhibitor for breast cancer is on hold while the drug company awaits results from it ovarian cancer trial, Leone said. Patients in the Phase III trial were stratified by BRCA 1 and BRCA 2 mutation.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.